Stella Mariss
Hello, everyone. Thank you for joining CLINUVEL’s Investor Webinar today. I’m Stella of Monsoon Communications. In today’s webinar, CLINUVEL will share the results and operational highlights for the financial year ended on the 30th June 2026.
I will now hand over to Malcolm Bull, Head of Australian Operations and Investor Relations, to conduct the proceedings.
Malcolm Bull
Head of Australian Operations & Investor Relations
Thank you, Stella, and thank you to Monsoon for hosting yet another CLINUVEL results webinar. Welcome, everybody, on the line. There should be 130 of you very attentive to the news that we’re going to provide to you. I have CFO, Peter Vaughan, on the line, as well as our Director of Global Clinical Affairs, Emilie Rodenburger on the line; and Managing Director, Philippe Wolgen. Welcome, executives.
The agenda today is to discuss our results for the financial year ending 30 June 2026. And we’re going to have Philippe and Peter and Emilie involved in various aspects of the performance and operations of the business. We also announced some other news today, the consideration of listing all of our ordinary shares on the NASDAQ and delisting from the ASX, and we’ll certainly get Philippe to talk to that. We have several analysts on the line who cover CLINUVEL, and

